الفهرس 
HCV EpidemiologyOnly 14 pages are availabe for public view
 |  | from | 143 |  |  |
| | | from | 143 | | |
Abstract
SUMMARY
Introduction:
Currently, according to WHO report, an estimated 71 million people have chronic hepatitis C infection worldwide. The most affected regions are Eastern Mediterranean and European Regions, with the prevalence of 2.3% and 1.5% respectively. Prevalence of HCV infection in other WHO regions varies from 0.5% to 1.0% (World Health Organization, 2017). Most of patients positive for HCV about (40% to 75%) present with symptomatic PN, being more prominent with HCV associated cryoglobulinemia (CG). Although presence of serum cryoglobulins is a prognostic marker of severe manifestation of PN, symptoms may be reported even in its absence, underlying a direct role of the virus in precipitating the disease (Carvalho-Filho et al., 2012).
The effect of the DAAs on HCV related EHM has only been reported in a few studies, a limited number of studies focused on the causal relationship between the DAAS of HCV and peripheral neuropathy (Gragnani et al., 2016).
Study settings:
This study was carried out in the out patients clinic and inpatients wards of neuropsychiatry department and tropical medicine in Tanta University Hospitals and Tanta educational Hospital from August 2017 to April 2018.